Oncologia Integral Satelite

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Lung cancer4 trials
• Prostate cancer2 trials

Phase

• Phase 36 trials

Status

• Active, not recruiting6 trials

Lead sponsor

• Janssen Research & Development, LLC4 trials
• Bayer1 trial
• Janssen Pharmaceutica N.V., Belgium1 trial

Running trials

• Recruiting

  A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  NCT06452277· Phase 3· Bayer· Source

• Active, not recruiting

  A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

  NCT04988295· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

  NCT04557059· Phase 3· Janssen Pharmaceutica N.V., Belgium· Source

• Active, not recruiting

  A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

  NCT04538664· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT04487080· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)

  NCT04497844· Phase 3· Janssen Research & Development, LLC· Source